Proof of Concept Study of ACH-0145228 in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Recruiting
Achillion Pharmaceuticals
Phase 2
The study will evaluate the efficacy and safety of the oral Factor D (FD) inhibitor ALXN2050
(ACH-0145228) monotherapy in patients with PNH that are treatment naïve, or patients
currently treated with eculizumab who still experience anemia and reticulocytosis, or
patients currently treated with ALXN2040 (danicopan) as monotherapy. After signing consent,
participants will have periodic visits through Week 12, at which time the primary endpoint
and key secondary assessments will be analyzed. Participants will continue on treatment past
12 weeks into a long-term extension portion of the trial.
Proof of Concept Study of ACH-0145228 in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Recruiting
Alexion Pharmaceuticals
Phase 2
The study will evaluate the efficacy and safety of the oral Factor D (FD) inhibitor ALXN2050
(ACH-0145228) monotherapy in patients with PNH that are treatment naïve, or patients
currently treated with eculizumab who still experience anemia and reticulocytosis, or
patients currently treated with ALXN2040 (danicopan) as monotherapy. After signing consent,
participants will have periodic visits through Week 12, at which time the primary endpoint
and key secondary assessments will be analyzed. Participants will continue on treatment past
12 weeks into a long-term extension portion of the trial.
A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants
Enrolling by invitation
Celerion
Phase 1
This will be an open-label, 3-sequence, 3-period crossover study in healthy adult
participants to assess the relative bioavailability of ACH-0145228 when administered as an
immediate release tablet versus powder-in-capsule.
A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants
Enrolling by invitation
Alexion Pharmaceuticals
Phase 1
This will be an open-label, 3-sequence, 3-period crossover study in healthy adult
participants to assess the relative bioavailability of ACH-0145228 when administered as an
immediate release tablet versus powder-in-capsule.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
